glp-1 receptor agonist medicines The New How GLP-1 medications are transforming
Description
References Abdul Basith Khan, M., Hashim, M., Kwan king, J., Devi Govender, R., Mustafa, H., & Al Kaabi, J
M.et al (2016)
One meta-analysis (April 2025) found no difference in incidence of aspiration (OR 1.04, 95% CI 0.871.25) despite the patients taking GLP-1 RAs having a higher incidence of residual gastric contents
136,169,170 With the accumulation of more clinical data and the development of new drugs, these treatment options are expected to provide more effective and comprehensive treatment choices for diabetes patients
The GLP-1 receptor is a type of cell surface receptor that binds to GLP-1, triggering a signaling cascade that leads to various effects, including the stimulation of insulin secretion, the inhibition of gastric emptying, and the promotion of satiety
On injecting the glucagon into patients with insulinomas at the Institute of Neurology, Marks was astonished to see that they developed an early and profound hypoglycaemia
